/ Source: Reuters
Neurocrine Biosciences Inc. said on Tuesday a late-stage trial of its highly anticipated insomnia drug helped elderly patients get to sleep and stay asleep during the night.
Neurocrine, which is developing the drug with partner Pfizer Inc., said it expects to submit a marketing application for the drug, indiplon, with U.S. regulators during the first half of this year.
The clinical trial results come less than a week after Sepracor Inc. received conditional U.S. approval for a sleep aid that is expected to be indiplon’s main rival.
